William Newell compensation by year
SUTRO BIOPHARMA Summary Compensation Table · all 9 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $467,620 | $482,000 | $496,500 | $554,000 | $625,000 | $662,500 | $686,667 | $707,500 | $239,693 |
| Bonus | $0 | $0 | $0 | — | — | — | — | $0 | $0 |
| Stock awards | $0 | $1,136,355 | $0 | $554,950 | $1,583,250 | $1,017,165 | $550,050 | $758,180 | $0 |
| Option awards | $0 | $6,764,993 | $3,097,200 | $707,500 | $2,994,000 | $948,972 | $520,663 | $589,373 | $0 |
| Non-equity incentive | $199,000 | $301,250 | $223,425 | $318,550 | $393,750 | $402,000 | $372,600 | $277,290 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $35,903 | $0 | $0 | $20,502 | $37,678 | $8,267 | — | $0 | $1,431,618 |
| Total | $702,523 | $8,684,598 | $3,817,125 | $2,155,502 | $5,633,678 | $3,038,904 | $2,129,979 | $2,332,343 | $1,671,311 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SUTRO BIOPHARMA, INC. DEF 14A filed April 22, 2026, accession 0001193125-26-170354, and prior-year filings. Open the filing on EDGAR.
How this page was built: the SUTRO BIOPHARMA, INC. filed document, accession 0001193125-26-170354. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2026.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 167,000 | $307,280 | — |
| RSU | 100,000 | $184,000 | — |
| RSU | 75,000 | $138,000 | — |
| RSU | 71,250 | $131,100 | — |
| RSU | 62,250 | $114,540 | — |
| RSU | 20,625 | $37,950 | — |
| RSU | 18,750 | $34,500 | — |
| RSU | 15,750 | $28,980 | — |
| Option | 10,375 | — | $8.17 |
| Option | 118,438 | — | $4.54 |
| Option | 22,937 | — | $4.54 |
| Option | 10,444 | — | $5.79 |
Per the Outstanding Equity Awards at Fiscal Year-End table in SUTRO BIOPHARMA, INC.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 16 award rows shown.
SUTRO BIOPHARMA’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| William Newell · this page | Former Chief Executive Officer | $1,671,311 |
| Jane Chung | Chief Executive Officer | $1,575,930 |
| Hans-Peter Gerber | Chief Scientific Officer | $942,902 |
| Gregory Chow | Chief Financial Officer | $854,522 |
Board service
SUTRO BIOPHARMA board · FY2021–FY2023How this board is paid
Company policy: SUTRO BIOPHARMA pays directors a $40,000 cash retainer and $25,000 in Options. As stated in SUTRO BIOPHARMA's FY2023 proxy.
The full SUTRO BIOPHARMA compensation record
free company briefThis page is one person within SUTRO BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the SUTRO BIOPHARMA proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order SUTRO BIOPHARMA's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SUTRO BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order STRO
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.